Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Focal adhesion kinase 1 (FAK) mRNA is the transcript of the PTK2 gene, which encodes a non-receptor tyrosine kinase localized at focal adhesions (Sulzmaier et al., 2014, Nature Reviews Cancer). FAK is a central integrator of signals from integrins and growth factor receptors, regulating fundamental cellular processes such as adhesion, migration, survival, and cell cycle progression (Tai et al., 2015, Journal of Biomedical Science). In the context of oncology, FAK mRNA is frequently overexpressed, contributing to the epithelial-to-mesenchymal transition (EMT), tumor invasion, and the maintenance of cancer stem cells (Lee et al., 2015, Pharmacology & Therapeutics). Therapeutic strategies targeting FAK mRNA, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), aim to silence the expression of the FAK protein entirely (Golubovskaya et al., 2009, Journal of Medicinal Chemistry). This approach is distinct from small-molecule inhibitors as it eliminates the scaffolding functions of FAK in addition to its catalytic activity, potentially overcoming resistance mechanisms observed with kinase inhibitors (Dawson et al., 2021, Cancer Research). Clinical and preclinical studies suggest that reducing FAK levels can enhance the efficacy of immunotherapy and chemotherapy by remodeling the tumor microenvironment (Jiang et al., 2016, Nature Medicine). Furthermore, targeting the mRNA transcript allows for high specificity, potentially reducing the off-target effects associated with multi-kinase inhibitors (Ucar et al., 2013, Molecular Therapy). Despite its potential, the clinical application of FAK mRNA-targeted therapies faces challenges related to stable delivery and efficient uptake in solid tumor tissues (Kanasty et al., 2013, Nature Materials).
RNA interference or antisense-mediated degradation of mRNA leading to reduced protein translation and depletion of both kinase and scaffolding functions
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Focal adhesion kinase 1 mRNA (FAK mRNA) (FAK mRNA).